Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens
- PMID: 2136907
- PMCID: PMC2187648
- DOI: 10.1084/jem.171.1.97
Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens
Abstract
When C3H (H-2k, Mls-1b) mice were primed intravenously with 10(8) viable spleen cells from AKR (H-2k, Mls-1a) and treated intraperitoneally with 200 mg/kg of cyclophosphamide (CP) 2 d later, not only a long-lasting skin allograft tolerance but also a tolerance in mixed lymphocyte reaction to Mls-1a-encoded antigens was established. The cellular mechanisms of CP-induced tolerance were examined by assessing the V beta 6-bearing T cells that are strongly correlated with reactivity to Mls-1a-encoded antigens bound to MHC class II molecules. At the relatively early stage (2 or 5 wk) after the CP treatment, CD4+-V beta 6+ T cells of C3H origin were preferentially eliminated in the lymph nodes of the tolerant mice, whereas CD8+-V beta 6+ T cells remained. On the other hand, neither CD4+CD8- nor CD4-CD8+ thymocytes bearing a high density of V beta 6 was detected in the chimeric thymus. Namely, in the thymus of the tolerant C3H mice, neither mixed chimerism nor the clonal deletion of the V beta 6-bearing T cells was observed on day 14, whereas both of them were observed on day 35. The clonal deletion and mixed chimerism in the thymus were lasting for greater than 10 wk after the CP treatment. Expression of V beta 6 on the peripheral T cells in the tolerant C3H mice gradually reduced in the process of time. These results strongly suggested that the clonal deletion in the thymus was one of the essential mechanisms in the CP-induced tolerance system.
Similar articles
-
The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance.Eur J Immunol. 1990 Sep;20(9):2005-13. doi: 10.1002/eji.1830200919. Eur J Immunol. 1990. PMID: 2209702
-
Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice.J Immunol. 1991 Mar 1;146(5):1402-9. J Immunol. 1991. PMID: 1671578
-
Similarity and difference in the mechanisms of neonatally induced tolerance and cyclophosphamide-induced tolerance in mice.J Immunol. 1991 Oct 15;147(8):2439-46. J Immunol. 1991. PMID: 1918974
-
Influence of graft versus host reaction on the T cell repertoire differentiating from bone marrow precursors following allogeneic bone marrow transplantation.Transpl Immunol. 1997 Jun;5(2):75-82. doi: 10.1016/s0966-3274(97)80046-9. Transpl Immunol. 1997. PMID: 9269028 Review.
-
T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens.Nature. 1988 Mar 3;332(6159):40-5. doi: 10.1038/332040a0. Nature. 1988. PMID: 3126397 Review.
Cited by
-
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.Semin Oncol. 2012 Dec;39(6):683-93. doi: 10.1053/j.seminoncol.2012.09.005. Semin Oncol. 2012. PMID: 23206845 Free PMC article. Review.
-
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.Cancer Immunol Immunother. 2013 Feb;62(2):383-91. doi: 10.1007/s00262-012-1343-0. Epub 2012 Aug 25. Cancer Immunol Immunother. 2013. PMID: 22926062 Free PMC article.
-
Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.Bone Marrow Transplant. 2014 Jul;49(7):873-9. doi: 10.1038/bmt.2014.19. Epub 2014 Feb 24. Bone Marrow Transplant. 2014. PMID: 24566712 Review.
-
TCR β chain-directed bispecific antibodies for the treatment of T cell cancers.Sci Transl Med. 2021 Mar 10;13(584):eabd3595. doi: 10.1126/scitranslmed.abd3595. Epub 2021 Mar 1. Sci Transl Med. 2021. PMID: 33649188 Free PMC article.
-
Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.J Clin Invest. 2019 Mar 26;129(6):2357-2373. doi: 10.1172/JCI124218. J Clin Invest. 2019. PMID: 30913039 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous